Epidiolex, a cannabis-based medicine recently approved by the FDA for the treatment of Dravet and Lennox-Gastaut syndromes, is the first drug containing Cannabidiol or CBD to be officially marketed for epilepsy therapy. Initially approved in June by the Food and Drug Administration (FDA), the US drug agency, the first Cannabidiol-based medicine against two epilepsy form is now available in the United States since November 1st.
The drug, which is an oral solution prepared by the British company GW Pharmaceuticals, is designed to treat Dravet and Lennox-Gastaut syndromes. “Because these patients have always reacted poorly to available medicines, there is an urgent need for new treatments to reduce the frequency and impact of seizures,” said Justin Gover, CEO of the pharmaceutical company, in a statement.
That is the first time that the FDA has approved a product based on Cannabis for medical use. That because Cannabidiol, even though it’s extracted from Cannabis, it